Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): A phase III, anaemia correction, morbidity-mortality trial

John J.V. McMurray, Inder S. Anand, Rafael Diaz, Aldo P. Maggioni, Christopher O'Connor, Marc A. Pfeffer, Krishna R. Polu, Scott D. Solomon, Yan Sun, Karl Swedberg, Michal Tendera, Dirk J. Van Veldhuisen, Scott M. Wasserman, James B. Young

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Abstract

BackgroundPatients with heart failure (HF) and anaemia have greater functional impairment, worse symptoms, increased rates of hospital admission, and a higher risk of death, compared with non-anaemic HF patients. Whether correcting anaemia can improve outcomes is unknown.ObjectiveThe Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF; Clinical Trials.gov NCT 003 58215) was designed to evaluate the effect of the long-acting erythropoietin-stimulating agent darbepoetin alfa on mortality and morbidity (and quality of life) in patients with HF and anaemia.MethodsApproximately 2600 patients with New York Heart Association class II-IV, an ejection fraction ≤40, and a haemoglobin (Hb) consistently ≤12.0 g/dL but ≥9.0 g/dL will be enrolled. Patients are randomized 1:1 to double-blind subcutaneous administration of darbepoetin alfa or placebo. Investigators are also blinded to Hb measurements and darbepoetin alfa is dosed to achieve an Hb concentration of 13.0 g/dL (but not exceeding 14.5 g/dL) with sham adjustments of the dose of placebo. The primary endpoint is the time to death from any cause or first hospital admission for worsening HF, whichever occurs first. The study will complete when ∼1150 subjects experience a primary endpoint.

Original languageEnglish (US)
Pages (from-to)795-801
Number of pages7
JournalEuropean Journal of Heart Failure
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2009

Keywords

  • Anaemia
  • Heart failure

Fingerprint

Dive into the research topics of 'Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): A phase III, anaemia correction, morbidity-mortality trial'. Together they form a unique fingerprint.

Cite this